June 12, 2019

Oak Therapeutics and the Department of Family Medicine at the University of Kansas Medical (KUMC) Center will cooperate on the development of Oral Dissolvable Strips for pediatric HIV antiretroviral prophylaxis in Kenya. The cooperation, which will be funded by the KUM...

October 1, 2016

We are proud to announce that we have received a contract from NIAID, the National Institute of Allergy and Infectious Diseases, a division of NIH, the National Institutes of Health. The contract enables us to develop a high-dose antibiotic Oral Dissolvable Strip (ODS)...

August 10, 2016

We are proud to report that we are in the final stages of negotiating an SBIR award with the National Institute for Allergens and Infectious Diseases (NIAID). The award will allow us to develop an oral dissolvable strip for Isoniazid, a pharmaceutical used in the treat...

February 29, 2016

On Friday, February 26th, the Pacific Coast Business Times announced the winners of the 2016 Central Coast Innovation Awards. We're proud to announce that Oak Therapeutics will be honored as the winner in the BioScience category! http://www.pacbiztimes.com/2016/02/26/c...

January 2, 2016

Ed Maliski, Ph.D. recently was interviewed by entrepreneur Mark Sylvester for the 805 Conversations podcast. Among other topics, Ed speaks about his starting of Cure Pharmaceuticals, his current role in Oak Therapeutics and - most importantly - his passion for providin...

July 26, 2015

Yesterday, a much-anticipated announcement was made on a variety of media outlets – European regulators approved Mosquirix, the first-ever malaria vaccine. Although this is an important first step, it is not the final blow to a disease that infects hundreds of millions...

July 25, 2015

We've had a pretty neat folder that describes what Oak Therapeutics is about for quite a while. This folder is now also online as a flip book. Check it out!

July 13, 2015

In it's July 3-9 edition, the Pacific Cost Business Times reported on the pre-clinical study that we just completed on our malaria product, Artelutrine, a combination of active ingredients Artemisinin and Lumefantrine.


July 10, 2015

We just released our new video on our contribution to solving the malaria problem. Our gratitude goes to Dariush Apfelthaler (vide0) as well as David "Blaze" Sepowski and David Decker (music). The video is available on YouTube.


June 25, 2015

Fresh from PR Log: Oxnard, CA – Oxnard-based pharmaceutical start-up Oak Therapeutics successfully concluded the pre-clinical phase of its anti-malarial medication Artelutrine™. Artelutrine™ is a reformulation of a highly effective, WHO-recommended combination therapy...

Please reload

Featured Posts

All of us at Oak Therapeutics are extremely proud to announce that we just concluded initial preclinical testing of our anti-malarial medication Artel...


June 17, 2015

Please reload

Recent Posts
Please reload

Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Oak Therapeutics, Inc., 2029 Becker Drive, Lawrence, KS 66047, United States, Tel. +1-913-346-0990, Email: office@oaktherapeutics.com